Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Emanuel Della-TorreCampochiaro CorradoGiulio CavalliGiacomo De LucaAngela NapolitanoSalvatore La MarcaNicola BoffiniValentina Da PratGaetano Di TerlizziMarco LanzillottaPatrizia Rovere QueriniAnnalisa RuggeriGiovanni LandoniMoreno TresoldiFabio CiceriALberto ZangrilloFrancesco De CobelliLorenzo Dagnanull nullnull nullPublished in: Annals of the rheumatic diseases (2020)
At day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- healthcare
- ejection fraction
- early onset
- chronic kidney disease
- newly diagnosed
- palliative care
- peritoneal dialysis
- prognostic factors
- cardiovascular events
- drug induced
- type diabetes
- quality improvement
- cardiovascular disease
- patient reported outcomes
- risk factors
- pain management
- intensive care unit
- coronary artery disease
- health insurance
- chronic pain
- patient reported
- affordable care act